Öz
Amaç
Çalışmamızın amacı, triple negatif meme kanseri (TNMK) hastalarında evreleme F-18 florodeoksiglikoz (FDG) pozitron emisyon tomografisi/bilgisayarlı tomografide (PET/BT) primer tümörün SUVmaks olarak tanımlanan FDG tutulumu ile aksiller lenf nodu (LN) metastazı ve Ki-67 ekspresyonu arasındaki ilişkiyi belirlemektir.
Yöntem
Temmuz 2021-Mart 2024 tarihlerinde birimimizde F-18 FDG PET/BT görüntülemesi yapılmış olan TNMK tanılı 136 kadın hasta retrospektif olarak değerlendirildi. Hastaların yaşları, histopatolojileri, hormon reseptör durumları, Ki-67 seviyeleri, tümör lokasyonları (sağ/sol), tümör ve aksiller LN’lerinin en büyük çapları, aksiller LN metastaz durumları, uzak metastaz varlığı ve yeri, T evreleri, klinik evreleri, primer tümör ve metastatik aksiller LN’lerin SUVmaks değerleri kayıt edildi.
Bulgular
Hastaların ortalama yaşı 51,42±13,14 yıl (aralık: 23-86) idi. Doksan beş (%69,85) hastada aksiller LN metastazı, 24 hastada (%17,65) uzak metastaz mevcut idi. Aksiller LN metastazı olan ve olmayan hastalar arasında yaş, Ki-67, tümör boyutu, tümör SUVmaks veya T evreleri açısından anlamlı bir fark izlenmedi. Tümör ve aksiller LN boyutları SUVmaksdeğerleri ile pozitif korelasyon gösterdi. Ki-67 ile tümör boyutu, tümör SUVmaks değeri, aksiller LN boyutu veya aksiller LN SUVmaks değerleri arasında bir korelasyon bulunamadı.
Sonuç
TNMK’de evreleme F-18 FDG PET/BT’den edilen primer tümör SUVmaks değeri ile aksiller LN metastazı veya Ki-67 proliferasyon indeksi arasında bir ilişki yoktur. Agresif malignitelerde beklenildiği gibi, primer tümör boyutu, tümör SUVmaks ve metastatik aksiller LN boyutu ile, aksiller LN boyutu ise aksiller LN SUVmaks değeri ile korelasyon göstermiştir.
Anahtar Kelimeler: Anahtar kelimeler: 18F-fluorodeoksiglukoz, aksiller lenf nodu, Ki-67, pozitron emisyon tomografisi, triple negatif meme kanseri
Kaynakça
Yan Z, Zhong Z, Shi C, Feng M, Feng X, Liu T. The prognostic marker KRT81 is involved in suppressing CD8 + T cells and predicts immunotherapy response for triple-negative breast cancer. Cancer Biol Ther. 2024;25(1):2355705.
van den Ende NS, Nguyen AH, Jager A, Kok M, Debets R, van Deurzen CHM. Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review. Int J Mol Sci. 2023;24(3):2969.
O’Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364(3):205-214.
Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012;118(22):5463-5472.
Banerjee M, George J, Song EY, Roy A, Hryniuk W. Tree-based model for breast cancer prognostication. J Clin Oncol. 2004;22(13):2567-2575.
Denkert C, Budczies J, von Minckwitz G, Wienert S, Loibl S, Klauschen F. Strategies for developing Ki67 as a useful biomarker in breast cancer. Breast. 2015:24(Suppl 2):S67-72.
Wu Q, Ma G, Deng Y, Luo W, Zhao Y, Li W, et al. Prognostic value of Ki-67 in patients with resected triple-negative breast cancer: a meta-analysis. Front Oncol. 2019;17(9):1068.
Vaz SC, Woll JPP, Cardoso F, Groheux D, Cook GJR, Ulaner GA, et al. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA). Eur J Nucl Med Mol Imaging. 2024;51(9):2706-2732.
Koo HR, Park JS, Kang KW, Han W, Park IA, Moon WK. Correlation between 18F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer. Eur Radiol. 2015;25(11):3314-3321.
Groheux D, Espie M, Giacchetti S, Hindie E. Performance of FDG PET/CT in the clinical management of breast cancer. Radiology. 2013;266(2):388-405.
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. Breast cancer, version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(3):310-320.
De Mooij CM, Ploumen RAW, Nelemans PJ, Mottaghy FM, Smidt ML, van Nijnatten TJA. The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis. EJNMMI Res. 2023;13(1):5.
Filippi L, Urso L, Ferrari C, Guglielmo P, Evangelista L. The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective. Eur J Nucl Med Mol Imaging. 2024;52(1):263-279.
Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38(3):426-435.
Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2007;34(12):1915-1924.
Arslan E, Çermik TF, Trabulus FDC, Talu ECK, Başaran Ş. Role of 18F-FDG PET/CT in evaluating molecular subtypes and clinicopathological features of primary breast cancer. Nucl Med Commun. 2018;39(7):680-690.
Tchou J, Sonnad SS, Bergey MR, Basu S, Tomaszewski J, Alavi A, et al. Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer. Mol Imaging Biol. 2010;12(6):657-662
Giuliano AE, Edge SB, Hortobagyi GN. Eighth edition of the AJCC cancer staging manual: breast cancer. Ann SurgOncol. 2018;25(7):1783-1785.
Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. European Association of Nuclear Medicine (EANM). FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging.2015;42(2):328-354.
Kim BS, Sung SH. Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer. Ann Nucl Med. 2012;26(2):175-183.
Jung NY, Kim SH, Kang BJ, Park SY, Chung MH. The value of primary tumor (18)F-FDG uptake on preoperative PET/CT for predicting intratumoral lymphatic invasion and axillary nodal metastasis. Breast Cancer. 2016;23(5):712-717.
Kim JY, Lee SH, Kim S, Kang T, Bae YT. Tumor 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes. Eur Radiol. 2015;25(4):1172-1181.
Rodriguez-Pinilla SM, Sarrió D, Honrado E, Hardisson D, Calero F, Benitez J, et al. Prognostic significance of basal-like phenotype and fascin expression in node negative invasive breast cancers. Clin Cancer Res. 2006;12(5):1533-1539.
Higuchi T, Nishimukai A, Ozawa H, Fujimoto Y, Yanai A, Miyagawa Y, et al. Prognostic significance of preoperative 18F-FDG PET/CT for breast cancer subtypes. Breast. 2016;30:5-12.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol. 2011;22(8):1736-1747.
Han JS, Cao D, Molberg KH, Sarode VR, Rao R, Sutton LM, et al. Hormone receptor status rather than HER2 status is significantly associated with increased Ki-67 and p53 expression in triple-negative breast carcinomas, and high expression of Ki-67 but not p53 is significantly associated with axillary nodal metastasis in triple-negative and high-grade non-triple-negative breast carcinomas. Am J Clin Pathol. 2011;135(2):230-237.
Groheux D, Biard L, Lehmann-Che J, Teixeira L, Bouhidel FA, Poirot B, et al. Tumour metabolism assessed by FDG-PET/CT and tumour proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer. Eur J Nucl Med Mol Imaging 2018;45(8):1279-1288.
Qu YH, Long N, Ran C, Sun J. The correlation of 18F-FDG PET/CT metabolic parameters, clinicopathological factors, and prognosis in breast cancer. Clin Transl Oncol. 2021;23(3):620-627.
